Finland's prostate cancer patterns revealed in large data review
NCT ID NCT05701007
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at over 1,000 men with metastatic prostate cancer in the Pirkanmaa region of Finland. Researchers analyzed patient characteristics, treatments used, and outcomes to better understand the disease burden. The goal was to fill gaps in knowledge about how these patients are treated and how the disease progresses in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,083 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Apr 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with advanced/metastatic prostate cancer and medical records available in the Hospital District of Pirkanmaa, Finland registry
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022 * Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC) * Detection of metastatic prostate cancer Exclusion Criteria: * Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014 * Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic castration sensitive prostate cancer (MCSPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Helsinki, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which prostate cancer drug delays the next treatment longer? a Real-World showdown
- Real-World study eyes drug combo for tough prostate cancer
- New radioactive therapy targets Hard-to-Treat prostate cancer
- New Immune-Boosting drug combo targets Hard-to-Treat cancers
- New prostate cancer drug enters first human trials
- CBD may cut opioid need in advanced prostate cancer